Skip to main content

Table 3 Summary of Mixed Model Results for PCM Items and PCM Index Scores

From: Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

 

Mixed Model Results

Endpoint

Change over time since Diagnosis

(Interval)

Change at Disease Progression

(Progression)

Change with Proximity to Progression

(Proximity)

Main or Interaction Effects

involving Regimen Group a

PCM Items

    

   Fatigue

Improving (p = .02)

Worsened (p = .004)

No effect

Progression: H = NT > T (p = .052)b

   Pain

No effect

Worsened (p = .051)

No effect

No effect

   Trouble Sleeping

No effect

No effect

No effect

Main effect: H = NT < T (p = .001)

PCM Index Scores

    

   General Physical Symptoms

Improving (p < .001)

Worsened (p < .001)

Tended to worsen leading into

progression, with less improvement

leading out (p = .088)

No effect

   Treatment Side Effects

Improving (p = .013)

Worsened (p < .001)

No main effect

Proximity: H = NT < T (p = .005) [Taxane had worse scores

distal from progression]

   Acute Distress

Improving (p = .002); improving faster

after progression (p = .022)

Worsened (p = .002)

No effect

No effect

   Despair and Depression

No effect

No effect

No effect

No effect

   Impaired Ambulation

No effect

No effect

No effect

No effect

   Impaired Performance

Improving (p = .003)

Worsened (p = .003)

No effect

Main effect: H < NT (p = .005) > T (p = .004)

  1. aH = Hormone therapy or no therapy, NT = Non-taxane based regimen, T = Taxane based regimen. Main effect = main effect of Regimen group; Progression = interaction of regimen group with Change at Progression; Proximity = interaction of regimen group with Change with Proximity to Progression. bP values are for specific contrasts involving regimen groups, with Taxane and Hormone only groups tested against the Non-taxane, which was the reference condition. P values for overall regimen effects are reported in the text where significant.